scispace - formally typeset
Journal ArticleDOI

What is the true solubility advantage for amorphous pharmaceuticals

Bruno C. Hancock, +1 more
- 01 Apr 2000 - 
- Vol. 17, Iss: 4, pp 397-404
Reads0
Chats0
TLDR
Amorphous pharmaceuticals are markedly more soluble than their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simplethermodynamic considerations.
Abstract
Purpose To evaluate the magnitude of the solubility advantage foramorphous pharmaceutical materials when compared to their crystallinecounterpartsMethods The thermal properties of several drugs in their amorphousand crystalline states were determined using differential scanningcalorimetry From these properties the solubility advantage for theamorphous form was predicted as a function of temperature using a simplethermodynamic analysis These predictions were compared to theresults of experimental measurements of the aqueous solubilities of theamorphous and crystalline forms of the drugs at several temperaturesResults By treating each amorphous drug as either an equilibriumsupercooled liquid or a pseudo-equilibrium glass, the solubilityadvantage compared to the most stable crystalline form was predicted to bebetween 10 and 1600 fold The measured solubility advantage wasusually considerably less than this, and for one compound studied indetail its temperature dependence was also less than predicted It wascalculated that even for partially amorphous materials the apparentsolubility enhancement (theoretical or measured) is likely to influencein-vitro and in-vivo dissolution behaviorConclusions Amorphous pharmaceuticals are markedly more solublethan their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simplethermodynamic considerations This appears to be the result of difficulties indetermining the solubility of amorphous materials under trueequilibrium conditions Simple thermodynamic predictions can provide a useful indication of the theoretical maximum solubility advantage foramorphous pharmaceuticals, which directly reflects the driving forcefor their initial dissolution

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Preparation and Characterization of Co-Grinded Mixtures of Aceclofenac and Neusilin US2 for Dissolution Enhancement of Aceclofenac

TL;DR: In vitro dissolution rate of acecl ofenac from co-ground mixture was significantly higher compared to pure aceclofenac and there was no reversion from amorphous to crystalline form, indicating that it is advantageous to use a porous carrier like Neusilin US2 in improvement of dissolution of poorly soluble drugs.
Journal ArticleDOI

Amorphous Active Pharmaceutical Ingredients in Preclinical Studies: Preparation, Characterization, and Formulation

TL;DR: In this article, a review of methods to generate the amorphous phase, estimate the degree of crystallinity of the polymeric phase, predict the stability of the ammorphous phase against crystallization, and choose the polymers carrier and formulation of the preclinical phase for preclinical studies is presented.
Journal ArticleDOI

Nanoparticle Formation and Growth During In Vitro Dissolution of Ketoconazole Solid Dispersion

TL;DR: The results suggested that the release of KC from the solid dispersions was carrier controlled initially, and PVP 17 PF is more efficient in inhibiting particle growth as compared with PVP-VA64, which may be an important consideration to achieve the full benefits of dissolution enhancement of solid dispersion.
Journal ArticleDOI

Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice.

TL;DR: High concentrations ofVRC in lung tissue coupled with clinically relevant plasma concentrations suggest that pulmonary delivery of microstructured crystalline VRC could potentially be a beneficial strategy for administration of VRC to patients with invasive pulmonary fungal infections.
References
More filters
Journal ArticleDOI

Characteristics and Significance of the Amorphous State in Pharmaceutical Systems

TL;DR: The amorphous state is critical in determining the solid-state physical and chemical properties of many pharmaceutical dosage forms and some of the most common methods that can be used to measure them are described.
Book

Polymorphism in Pharmaceutical Solids

TL;DR: Brittain et al. as mentioned in this paper applied the phase rule to the characterisation of polymorphic and solvatomorphic systems, and proposed a computational method to predict polymorphism.
Journal ArticleDOI

Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations

TL;DR: It is hoped that this review will lead to a more direct approach to the characterization of pharmaceuticalsolids and ultimately to faster approval of regulatory documents containing information on pharmaceutical solids.
Journal ArticleDOI

Crystallization of Indomethacin from the Amorphous State below and above Its Glass Transition Temperature

TL;DR: It was shown that in both samples significant crystallization to the most stable polymorphic form occurred over several days when stored below Tg, and in some cases this process was preceded by the relaxation of one amorphous form to the other.
Journal ArticleDOI

Characterization of the time scales of molecular motion in pharmaceutically important glasses

TL;DR: In this paper, the authors characterized the molecular mobility of selected amorphous systems (i.e., indomethacin, sorbitol, sucrose, and trehalose) below Tg using a combined experimental and theoretical approach.
Related Papers (5)